|Bid||51.59 x 1100|
|Ask||51.59 x 800|
|Day's range||50.03 - 51.86|
|52-week range||41.45 - 61.71|
|Beta (5Y monthly)||0.65|
|PE ratio (TTM)||9.88|
|Earnings date||06 Feb 2023 - 10 Feb 2023|
|Forward dividend & yield||1.60 (3.22%)|
|Ex-dividend date||03 Nov 2022|
|1y target est||54.78|
A U.S. district court dismisses thousands of lawsuits involving Zantac. Relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE).
The FDA's decision on Pfizer's (PFE) BLA seeking approval for RSV vaccine candidate in older adults is expected in May 2023.
NEW YORK & MAINZ, Germany, December 08, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age. Children in this age group can receive a primary series consisting of two 3-µg doses of the original Pfizer-BioNTech COVID-19 Vaccine